ReShape Lifesciences's total assets for Q3 2024 were $5.62M, a decrease of -12.17% from the previous quarter. RSLS total liabilities were $4.13M for the fiscal quarter, a 22.93% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.